Cargando…
Aflibercept ameliorates retinal pericyte loss and restores perfusion in streptozotocin-induced diabetic mice
INTRODUCTION: Anti-vascular endothelial growth factor (VEGF) agents are used worldwide for advanced-stage diabetic retinopathy (DR). In contrast, apart from blood glucose control, there are no specific treatments that can limit the progression of early-stage DR that starts with pericyte loss and the...
Autores principales: | Seo, Eoi Jong, Choi, Jeong A, Koh, Jae-Young, Yoon, Young Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574888/ https://www.ncbi.nlm.nih.gov/pubmed/33077473 http://dx.doi.org/10.1136/bmjdrc-2020-001278 |
Ejemplares similares
-
Pericyte Migration: A Novel Mechanism of Pericyte Loss in Experimental Diabetic Retinopathy
por: Pfister, Frederick, et al.
Publicado: (2008) -
Retinal Arteriolar Dilation Predicts Retinopathy in Adolescents With Type 1 Diabetes
por: Cheung, Ning, et al.
Publicado: (2008) -
Histamine causes an imbalance between pro-angiogenic and anti-angiogenic factors in the retinal pigment epithelium of diabetic retina via H4 receptor/p38 MAPK axis
por: Lee, Byung Joo, et al.
Publicado: (2020) -
Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018) -
Prediction of protective sensory loss, neuropathy and foot ulceration in type 2 diabetes
por: Paisey, R B, et al.
Publicado: (2016)